Inactive Instrument

Xynomic Pharmaceuticals Holdings, Inc.

XYN

US98421X1028

Xynomic Pharma Doses First Chinese Patient in Pivotal Phase 3 Kidney Cancer Trial

September 13, 2019 at 03:58 pm EDT

Xynomic Pharmaceuticals Holdings, Inc. announced the dosing of the first Chinese patient in its on-going global pivotal Phase 3 trial of Xynomic’s abexinostat combined with pazopanib as a first- or second-line therapy against renal cell carcinoma (RCC) at Peking University Cancer Hospital & Institute. Dr. Jun Guo, Professor and Medical Director at Peking University Cancer Hospital & Institute, is the leading principal investigator for this trial in China.

Latest news about Xynomic Pharmaceuticals Holdings, Inc.

Xu-Nuo Pharma, Inc. acquired the remaining 2% stake in Xynomic Pharmaceuticals Holdings, Inc..	21-06-16	CI
Xynomic Pharmaceuticals Holdings, Inc. Announces Resignation of Richard Peidong Wu as Independent Director and the Chairman of the Audit Committee	20-06-29	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-06-01	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-14	CI
Xynomic Pharmaceuticals Holdings, Inc. Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma	19-09-23	CI
Xynomic Pharmaceuticals Holdings, Inc. Announces Management Changes	19-09-20	CI
Xynomic Pharma Doses First Chinese Patient in Pivotal Phase 3 Kidney Cancer Trial	19-09-13	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda in Multiple Solid Tumors	19-08-30	CI
Xynomic Research Institute Has Successfully Designed a Series of Potent RET Kinase Inhibitors	19-08-16	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-15	CI
Xynomic Pharmaceuticals Holdings, Inc. Approves Application to Conduct Pivotal Phase 3 Trial Using Abexinostat	19-08-07	CI
Xynomic Pharmaceuticals Holdings, Inc. Files Fast-Track Designation Application for Follicular Lymphoma Treatment with the U.S. FDA	19-08-01	CI
Xynomic Pharmaceuticals Holdings, Inc. Receives China Approval to Start 2 Pivotal Lymphoma Clinical Trials	19-07-30	CI
Xynomic Pharmaceuticals Holdings, Inc. announced that it expects to receive $14.999998 million in funding	19-07-09	CI
Xynomic Pharmaceuticals Holdings, Inc. Announces Board Changes	19-07-05	CI
Xynomic Pharmaceuticals Holdings, Inc. Completes Pre-IND Meeting with US FDA for XP-102	19-06-12	CI
Xynomic Pharmaceuticals Holdings, Inc. Doses First Patient in Phase 1/2 Lymphoma Trial	19-06-06	CI
Xynomic Pharmaceuticals Holdings, Inc.(NasdaqCM:XYN) added to NASDAQ Composite Index	19-05-15	CI
Xynomic Pharmaceuticals, Inc completed the acquisition of Bison Capital Acquisition Corp. in a reverse merger transaction.	19-05-14	CI
Xynomic Pharmaceuticals, Inc Appoints Jinwei Coco Kou as the Interim Chief Accounting Officer	19-03-20	CI
China, Spain and Poland Authorities Approves Xynomic Pharmaceuticals, Inc.'s Application	19-03-16	CI
Xynomic Pharma Appoints Dr. Sophia Paspal as the Vice President, Regulatory Affairs and Quality Assurance	19-02-27	CI
Xynomic Pharma Will Present at ASCO-GU Cancers Symposium, Files 3 INDs for Potentially Pivotal Cancer Trials in China, and Expands R&D Operations	18-12-27	CI
Xynomic Pharmaceuticals, Inc entered into a non-binding letter of intent to acquire Bison Capital Acquisition Corp. in a reverse merger transaction.	18-09-11	CI
Xynomic Pharmaceuticals, Inc. announced that it has received funding from Northern Light Venture Capital, Hakim Unique Internet Co., Ltd., Shanghai Prosperico Ventures Co., Ltd., and other investors	18-05-31	CI

Chart Xynomic Pharmaceuticals Holdings, Inc.

Duration

Period

Chart Xynomic Pharmaceuticals Holdings, Inc.

More charts

Company Profile

XYNOMIC PHARMACEUTICALS HOLDINGS, INC. is a China-based biopharmaceutical company. The Company, together with its subsidiaries, are principally engaged in in-licensing, developing and commercializing oncology drug candidates in the People's Republic of China (PRC), the United States, and rest of the world. To date, the Company has not yet generated any revenue from product sales.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-3.54%	86.16B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.17B
BIOGEN INC.	-17.49%	31.47B
UCB	+54.44%	25.24B
BIOMARIN PHARMACEUTICAL INC.	-13.13%	15.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.96B
INCYTE CORPORATION	-15.45%	11.89B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.84B

Biopharmaceuticals